Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)
Close on Nov 17, 2026Market cap $8.27BP/E –Yield –
Spyre Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Spyre Therapeutics's operating margin for the twelve months ending Mar 31, 2024 was -39428.9%. For fiscal 2023 it was -27348.0%, against -3640.2% the year before. The highest annual figure on record is -350.3% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -27348.0% | −23707.7 |
| FY2022 | Dec 31, 2022 | -3640.2% | −3289.9 |
| FY2021 | Dec 31, 2021 | -350.3% | +819.0 |
| FY2018 | Dec 31, 2018 | -1169.3% | −637.6 |
| FY2017 | Dec 31, 2017 | -531.7% | −58.4 |
| FY2016 | Dec 31, 2016 | -473.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -23146.2% | −19558.5 |
| Q1 FY2023 | Mar 31, 2023 | -9498.0% | −7703.5 |
| Q4 FY2022 | Dec 31, 2022 | -11406.0% | −10845.0 |
| Q3 FY2022 | Sep 30, 2022 | -10778.7% | −9328.2 |
| Q2 FY2022 | Jun 30, 2022 | -3587.7% | −3538.7 |
| Q1 FY2022 | Mar 31, 2022 | -1794.5% | −1387.8 |
| Q4 FY2021 | Dec 31, 2021 | -561.0% | −15.0 |
| Q3 FY2021 | Sep 30, 2021 | -1450.5% | −1003.7 |
| Q2 FY2021 | Jun 30, 2021 | -49.0% | +585.3 |
| Q2 FY2018 | Jun 30, 2018 | -406.6% | +47.7 |
| Q1 FY2018 | Mar 31, 2018 | -546.0% | +98.7 |
| Q4 FY2017 | Dec 31, 2017 | -446.9% | – |
| Q3 FY2017 | Sep 30, 2017 | -634.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -454.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -644.7% | – |
See a number that looks wrong?